Immutep Limited
NASDAQ: IMMP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc Voigt
- Employees
- 53
- Headquarters
- Sydney, Australia
- IPO year
- 2012
- Market cap
- $57.2M
- Website
- https://www.immutep.com
Loading IMMP…
Loading profile data…Frequently asked questions about IMMP
What does Immutep Limited (IMMP) do?
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of c...
Where does IMMP trade?
Immutep Limited (IMMP) trades on the NASDAQ.
What sector is IMMP in?
Immutep Limited (IMMP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Immutep Limited?
Marc Voigt is the chief executive officer of Immutep Limited (IMMP).
Where is Immutep Limited headquartered?
Immutep Limited is headquartered in Australia.
Does IMMP pay a dividend?
Immutep Limited (IMMP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IMMP go public?
Immutep Limited (IMMP) completed its initial public offering in 2012.